Log in to save to my catalogue

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant...

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_232c37a650224a71b52e995656347cde

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

About this item

Full title

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Publisher

London, England: SAGE Publications

Journal title

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.17588359221081922-17588359221081922

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of m...

Alternative Titles

Full title

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_232c37a650224a71b52e995656347cde

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_232c37a650224a71b52e995656347cde

Other Identifiers

ISSN

1758-8359,1758-8340

E-ISSN

1758-8359

DOI

10.1177/17588359221081922

How to access this item